Why Calidi Biotherapeutics (CLDI) Stock Is Down 13%

Calidi Biotherapeutics Inc CLDI shares are trading lower by 13.3% to 98 cents during Wednesday’s session after the company announced it entered a securities purchase agreement with institutional investors for the sale of 2,050,000 shares of common stock at $1.00 per share in a registered direct offering.

What Else: Additionally, in a concurrent private placement, the company will issue series E and F warrants, allowing investors to purchase up to 2,050,000 more shares at $1.13 per share.

The series E warrants are exercisable six months after issuance and have a one-year term, while series F warrants have a five-year term.

The transactions are expected to close around October 24, with Ladenburg Thalmann & Co. acting as the exclusive placement agent.

Read Also: Tesla Stock Faces Selling Pressure Ahead Of Q3 Earnings: 4 Takeaways From The Chart

How To Buy CLDI Stock

Besides going to a brokerage platform to purchase a share – or fractional share – of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument.

For example, in Calidi Biotherapeutics’ case, it is in the Health Care sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.

According to data from Benzinga Pro, CLDI has a 52-week high of $29.30 and a 52-week low of $0.96.